Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older~2. Able to provide informed consent~3. Hospitalized adult patients with pneumonia evidenced by chest X-ray or CT scan~4. Laboratory (RT-PCR) confirmed infection with 2019-nCoV or strongly suspected to be infected with SARS-COV2 with confirmation studies pending~5. And at least one of the following:~   1. Respiratory frequency ≥30/min~  2. Blood oxygen saturation ≤93% on RA~  3. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) \<300~  4. Worsening of lung involvement, defined as an increase in number and/or extension of pulmonary areas of consolidation, need for increased FiO2 to maintain stable O2 saturation, or worsening O2 saturation of \>3% with stable FiO2~Exclusion Criteria:~1. Treatment with any TNFα inhibitor in the past 30 days~2. Known hypersensitivity to any TNFα inhibitor, murine proteins, or any component of the formulation~3. Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 1000 mm3, hemoglobin \<8.0g/L, platelets \<50,000 per mm3, or AST or ALT greater than 5 x ULN~4. Known active or latent Hepatitis B~5. Known or suspected active tuberculosis (TB) or a history of incompletely treated or latent TB.~6. Pregnancy~7. Intubated for \>48hours~8. Patients with uncontrolled systemic bacterial or fungal infections (Patients with a history of positive bacterial or fungal cultures but on enrollment are on appropriate therapy with negative repeat cultures may be enrolled)~9. Serious co-morbidity, including:~   1. Myocardial infarction (within last month)~  2. Moderate or severe heart failure (New York Heart Association (NYHA) class III or IV)~  3. Acute stroke (within last month)~  4. Uncontrolled malignancy~  5. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular filtration rate (eGFR) \< 30 ml /min/1.73 m\^2) at baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab (Type: EXPERIMENTAL): All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).